Filtered By:
Condition: Pneumonia
Vaccination: Vaccines
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 29 results found since Jan 2013.
Flu jab "may cut" stroke risk by a quarter
ConclusionThis research finds that, overall, having the flu vaccine reduced the risk of a person experiencing a stroke by about 25%. The reduction in risk seemed to be greatest within the first three months of vaccination, but remained for up to 12 months. However, the effect lasted only if the vaccine was given early in the flu season (September to mid-November); giving the vaccine late in the flu season (mid-November to February) was not associated with significantly reduced risk.The research benefits from using data coded within the General Practice Research Database for England and Wales for almost 50,000 people with...
Source: NHS News Feed - February 21, 2014 Category: Consumer Health News Tags: Heart/lungs Neurology Older people Source Type: news
Influenza vaccination and 1-year risk of myocardial infarction, stroke, heart failure, pneumonia, and mortality among intensive care unit survivors aged 65 years or older: a nationwide population-based cohort study
ConclusionsCompared with the unvaccinated ICU survivors, the influenza vaccinated ICU survivors had a lower 1-year risk of stroke and a lower 1-year risk of death, whereas no substantial association was observed for the risk of hospitalization for myocardial infarction, heart failure, or pneumonia. Our findings support influenza vaccination of individuals aged ≥ 65 years.
Source: Intensive Care Medicine - June 10, 2019 Category: Intensive Care Source Type: research
Relative Burden of Community-Acquired Pneumonia Hospitalizations in Seniors
Conclusions Although CAP has a higher burden of hospitalization and total costs than MI, stroke, and OF in the elderly population, prevention efforts are much smaller for CAP. Prioritization of CAP prevention is needed to substantially reduce its burden.
Source: American Journal of Preventive Medicine - July 12, 2016 Category: Global & Universal Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans
CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that there were few differences in risk of adverse events within 14 days of the first dose of either the BNT162b2 or the mRNA-1273 vaccine and small-magnitude differences within 42 days of the first dose. The 38-week risks of adverse events were low in both vaccine groups, although risks were lower for recipients of the mRNA-1273 vaccine than for recipients of the BNT162b2 vaccine. Although the primary analysis was designed to detect safety events unrelated to SARS-CoV-2 infection, the possibility that these differences may partially be explained by a low...
Source: Herpes - June 13, 2022 Category: Infectious Diseases Authors: Barbra A Dickerman Arin L Madenci Hanna Gerlovin Katherine E Kurgansky Jessica K Wise Michael J Figueroa Mu ñiz Brian R Ferolito David R Gagnon J Michael Gaziano Kelly Cho Juan P Casas Miguel A Hern án Source Type: research
Differences in predictors of 5‐year survival over a 10‐year period in two cohorts of elderly nursing home residents in Sweden
ConclusionsThe present results indicate a trend that individuals are older and frailer when admitted to NH and that survival time after admission has been shortened. Hence, the need of daily support and care has increased, irrespective of housing. Also, predictors of survival, possible to influence, have changed.
Source: Scandinavian Journal of Caring Sciences - February 4, 2016 Category: Nursing Authors: Märta Sund Levander, Anna Milberg, Nils Rodhe, Pia Tingström, Ewa Grodzinsky Tags: Empirical Studies Source Type: research
Differences in predictors of 5 ‐year survival over a 10‐year period in two cohorts of elderly nursing home residents in Sweden
ConclusionsThe present results indicate a trend that individuals are older and frailer when admitted to NH and that survival time after admission has been shortened. Hence, the need of daily support and care has increased, irrespective of housing. Also, predictors of survival, possible to influence, have changed.
Source: Scandinavian Journal of Caring Sciences - February 3, 2016 Category: Nursing Authors: M ärta Sund Levander, Anna Milberg, Nils Rodhe, Pia Tingström, Ewa Grodzinsky Tags: Empirical Studies Source Type: research
Assessment of pre-specified adverse events following varicella vaccine: A population-based self-controlled risk interval study.
CONCLUSIONS: We detected a small risk of incidental pneumonia associated with varicella vaccine in the 6th week after immunization. There was no increase in the risk of other pre-specified adverse events.
PMID: 32046891 [PubMed - as supplied by publisher]
Source: Vaccine - February 7, 2020 Category: Allergy & Immunology Authors: Liu CH, Yeh YC, Huang WT, Chie WC, Chan KA Tags: Vaccine Source Type: research
Clinical features of adults with seven-valent-conjugated-vaccine-serotype pneumococcal pneumonia.
CONCLUSION: A significant proportion of adults continue to develop PCV7-serotype CAP in the era of childhood pneumococcal conjugate vaccination. These adults are more likely to have stroke and dementia as underlying co-morbid illnesses, and have a higher 30-day mortality. A combination of pneumococcal transmission factors, host factors and pneumococcal serotype specific characteristics are likely to explain these findings.
PMID: 24508039 [PubMed - as supplied by publisher]
Source: Vaccine - February 6, 2014 Category: Allergy & Immunology Authors: Rodrigo C, Bewick T, Sheppard C, Greenwood S, Trotter C, Slack M, George R, Lim WS Tags: Vaccine Source Type: research
Get the flu vaccine, reduce your risk of death
Last year was a lousy year for the flu vaccine. Hospitalizations for flu hit a nine-year high, and the vaccine prevented flu in only 23% of all recipients, compared with 50% to 60% of recipients in prior years.
Why does the flu vaccine work well in some winters and not others? The flu vaccine primes the immune system to attack two proteins on the surface of the influenza A virus, hemagglutinin (H) and neuraminidase (N). Different flu strains have different combinations of these proteins — for example, the strains targeted by recent flu vaccines are H3N2 and H1N1.
Unfortunately, the influenza virus is microbiology’s ans...
Source: New Harvard Health Information - September 15, 2015 Category: Consumer Health News Authors: John Ross, MD, FIDSA Tags: Cold and Flu Vaccines Flu Shot flu vaccine Source Type: news
Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes.
Authors: Vamos EP, Pape UJ, Curcin V, Harris MJ, Valabhji J, Majeed A, Millett C
Abstract
BACKGROUND: The health burden caused by seasonal influenza is substantial. We sought to examine the effectiveness of influenza vaccination against admission to hospital for acute cardiovascular and respiratory conditions and all-cause death in people with type 2 diabetes.
METHODS: We conducted a retrospective cohort study using primary and secondary care data from the Clinical Practice Research Datalink in England, over a 7-year period between 2003/04 and 2009/10. We enrolled 124 503 adults with type 2 diabetes. Outcome me...
Source: Canadian Medical Association Journal - July 28, 2016 Category: Journals (General) Tags: CMAJ Source Type: research
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
AbstractReports of cerebral venous sinus thrombosis and intracranial hemorrhage (ICH) following the administration of coronavirus vaccines have raised concerns regarding their safety. Although no regulatory authority has recognized ICH as an adverse event associated with tozinameran (BNT162b2, Pfizer-BioNTech), fatal and non-fatal cases have been reported. In Japan, 10 fatal cases (five men and women) have been reported to date. Four of the five women died of ICH and the other died of aspiration pneumonia, whereas all five men died of causes other than stroke. This imbalance is incompatible with the mortality data on cardi...
Source: Journal of Pharmaceutical Policy and Practice - May 31, 2021 Category: Pharmaceuticals Source Type: research
Flu and freezing weather may be driving up winter death rates
Conclusion
There are always more deaths in winter than other seasons, particularly among elderly people. But why these fairly dramatic spikes in the death rate have occurred is still not understood.
It should be noted these figures are provisional, as there can be a delay in the ONS receiving the data.
Although the media has focused on the likely cause being flu, the numbers provided are for all respiratory conditions. Cold weather can exacerbate many of these conditions, such as asthma and chronic obstructive pulmonary disease.
For most fit and healthy people, flu is not a serious threat, but the elderly and those with...
Source: NHS News Feed - February 4, 2015 Category: Consumer Health News Tags: Heart/lungs Lifestyle/exercise Medical practice QA articles Source Type: news
Kids and flu shots: Two common myths
As a pediatrician, I am really passionate about the flu shot. Influenza can be a nasty illness; every year, thousands of people are hospitalized with influenza and its complications, and some of those people die. The flu shot can protect my patients and their families, and I enthusiastically recommend it to all of them.
And yet many of them refuse, despite my best efforts. What is particularly frustrating is that many of them refuse because of misunderstandings about the flu shot. There is all sorts of misinformation out there, but here are the two most common myths:
1. The flu shot can make you sick. This is the one I hea...
Source: New Harvard Health Information - October 9, 2015 Category: Consumer Health News Authors: Claire McCarthy, MD Tags: Cold and Flu Vaccines flu vaccine Source Type: news
Do statins interfere with the flu vaccine?
Statins are powerful, unusual, and, like El Niño and Tom Cruise, not well understood. Statins have a huge upside. They improve survival after heart attacks and lower the risk of recurrent strokes. They are also the only cholesterol-lowering medications that have been clearly shown to reduce heart attacks and deaths in high-risk patients without heart disease. In addition to reducing cholesterol, statins also lower levels of inflammation in the body. Reducing inflammation probably helps statins to prevent heart attack and stroke. However, evidence is emerging that these statin effects may also have a downside, hindering th...
Source: New Harvard Health Information - November 30, 2015 Category: Consumer Health News Authors: John Ross, MD, FIDSA Tags: Cold and Flu Drugs and Supplements Health Heart Health Vaccines flu vaccine statins Source Type: news
